Home › Uveal Melanoma
Pag-aaral pangklinika para sa Uveal Melanoma na nagre-recruit sa U.S.
22 pag-aaral para sa Uveal Melanoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Philadelphia, PA7 pag-aaral
- Los Angeles, CA6 pag-aaral
- Nashville, TN6 pag-aaral
- New York City, NY5 pag-aaral
- Boston, MA5 pag-aaral
- Columbus, OH5 pag-aaral
- Houston, TX5 pag-aaral
- Scottsdale, AZ5 pag-aaral
- Denver, CO5 pag-aaral
- Miami, FL4 pag-aaral
- Tampa, FL4 pag-aaral
- Mountain View, CA4 pag-aaral
- Aurora, CO4 pag-aaral
- Pittsburgh, PA4 pag-aaral
- Chicago, IL3 pag-aaral
- Cleveland, OH3 pag-aaral
- Madison, WI3 pag-aaral
- Durham, NC3 pag-aaral
Ayos sa estado
- Arizona5 pag-aaral
- California7 pag-aaral
- Colorado7 pag-aaral
- Florida8 pag-aaral
- Illinois3 pag-aaral
- Massachusetts5 pag-aaral
- Michigan3 pag-aaral
- New York7 pag-aaral
- North Carolina4 pag-aaral
- Ohio8 pag-aaral
- Pennsylvania8 pag-aaral
- Tennessee6 pag-aaral
- Texas5 pag-aaral
- Wisconsin3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05607095Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07804186Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06070012A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT07636785Tebentafusp-tebn With LDT in Metastatic UM
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 21, 2026 · NCT06626516Adjuvant Tebentafusp in High Risk Ocular Melanoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06246149Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT06961357Adjuvant Quisinostat in High-Risk Uveal Melanoma
Nagre-recruitPhase 2
Edad 19 pataas · Lahat ng kasarian · Na-update Hun 18, 2026 · NCT06932757A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Nagre-recruitPhase 1/2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT06940739Neoadjuvant Tebentafusp for Uveal Melanoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT06414590Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Nagre-recruitPhase 2/3
Lahat ng edad · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT06581406Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 31, 2026 · NCT07276386Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT04119024Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 11, 2026 · NCT07364474Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Lahat ng edad · Lahat ng kasarian · Na-update Mar 9, 2026 · NCT04792463Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 23, 2026 · NCT06627244Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 4, 2025 · NCT06121180Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 28, 2025 · NCT07136181A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2025 · NCT06805825Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.